GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PhenomeX Inc (NAS:CELL) » Definitions » ROE %

PhenomeX (PhenomeX) ROE % : -149.42% (As of Jun. 2023)


View and export this data going back to 2020. Start your Free Trial

What is PhenomeX ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. PhenomeX's annualized net income for the quarter that ended in Jun. 2023 was $-200.98 Mil. PhenomeX's average Total Stockholders Equity over the quarter that ended in Jun. 2023 was $134.51 Mil. Therefore, PhenomeX's annualized ROE % for the quarter that ended in Jun. 2023 was -149.42%.

The historical rank and industry rank for PhenomeX's ROE % or its related term are showing as below:

CELL' s ROE % Range Over the Past 10 Years
Min: -83.73   Med: -25.31   Max: -20.18
Current: -83.73

During the past 5 years, PhenomeX's highest ROE % was -20.18%. The lowest was -83.73%. And the median was -25.31%.

CELL's ROE % is not ranked
in the Biotechnology industry.
Industry Median: -44.1 vs CELL: -83.73

PhenomeX ROE % Historical Data

The historical data trend for PhenomeX's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PhenomeX ROE % Chart

PhenomeX Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22
ROE %
-23.90 -20.18 -25.31 -31.67 -55.98

PhenomeX Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -56.03 -51.87 -78.07 -62.49 -149.42

Competitive Comparison of PhenomeX's ROE %

For the Biotechnology subindustry, PhenomeX's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PhenomeX's ROE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PhenomeX's ROE % distribution charts can be found below:

* The bar in red indicates where PhenomeX's ROE % falls into.



PhenomeX ROE % Calculation

PhenomeX's annualized ROE % for the fiscal year that ended in Dec. 2022 is calculated as

ROE %=Net Income (A: Dec. 2022 )/( (Total Stockholders Equity (A: Dec. 2021 )+Total Stockholders Equity (A: Dec. 2022 ))/ count )
=-98.04/( (208.216+142.055)/ 2 )
=-98.04/175.1355
=-55.98 %

PhenomeX's annualized ROE % for the quarter that ended in Jun. 2023 is calculated as

ROE %=Net Income (Q: Jun. 2023 )/( (Total Stockholders Equity (Q: Mar. 2023 )+Total Stockholders Equity (Q: Jun. 2023 ))/ count )
=-200.98/( (157.74+111.281)/ 2 )
=-200.98/134.5105
=-149.42 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Jun. 2023) net income data. ROE % is displayed in the 30-year financial page.


PhenomeX  (NAS:CELL) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Jun. 2023 )
=Net Income/Total Stockholders Equity
=-200.98/134.5105
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-200.98 / 56.248)*(56.248 / 239.4465)*(239.4465 / 134.5105)
=Net Margin %*Asset Turnover*Equity Multiplier
=-357.31 %*0.2349*1.7801
=ROA %*Equity Multiplier
=-83.93 %*1.7801
=-149.42 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Jun. 2023 )
=Net Income/Total Stockholders Equity
=-200.98/134.5105
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-200.98 / -200.776) * (-200.776 / -118.228) * (-118.228 / 56.248) * (56.248 / 239.4465) * (239.4465 / 134.5105)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1.001 * 1.6982 * -210.19 % * 0.2349 * 1.7801
=-149.42 %

Note: The net income data used here is four times the quarterly (Jun. 2023) net income data. The Revenue data used here is four times the quarterly (Jun. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


PhenomeX ROE % Related Terms

Thank you for viewing the detailed overview of PhenomeX's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


PhenomeX (PhenomeX) Business Description

Traded in Other Exchanges
N/A
Address
5858 Horton Street, Suite 320, Emeryville, CA, USA, 94608
PhenomeX Inc is a functional cell biology company that provides live cell biology research tools which deliver deep insights into cellular function and new perspectives on phenomes.
Executives
Siddhartha Kadia director, officer: Chief Executive Officer 7475 LUSK BOULEVARD, SAN DIEGO CA 92121
Mehul Joshi officer: Chief Financial Officer C/O BERKELEY LIGHTS, INC., 5858 HORTON STREET, SUITE 320, EMERYVILLE CA 94608
Peter Silvester director C/O BERKELEY LIGHTS, INC., 5858 HORTON STREET, SUITE 320, EMERYVILLE CA 94608
John R Chiminski director C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Jessica Hopfield director C/O 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
Bird Mergersub Corp 10 percent owner 40 MANNING ROAD, BILLERICA MA 01821
Bruker Corp 10 percent owner 40 MANNING RD, BILLERICA MA 01821
James Paul Mcclaskey officer: SVP, Chief Accounting Officer C/O BERKELEY LIGHTS, INC., C/O BERKELEY LIGHTS, INC., EMERYVILLE CA 94608
Scott David Chaplin officer: Chief Legal Officer 3101 WILSON BOULEVARD, SUITE 700, ARLINGTON VA 22201
Eric Hobbs director, officer: Chief Executive Officer C/O BERKELEY LIGHTS, INC., 5858 HORTON STREET, SUITE 320, EMERYVILLE CA 94608
James Rothman director 135 EAST 83RD STREET, APT. 15C, NEW YORK NY 10028
Gregory T Lucier director C/O DENTSPLY SIRONA INC, 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277
Keith Breinlinger officer: Chief Technical Officer C/O BERKELEY LIGHTS, INC., 5858 HORTON STREET, SUITE 320, EMERYVILLE CA 94608
Igor Y Khandros director, 10 percent owner 25 HACIENDAS ROAD, ORINDA CA 94563
Stuart L Merkadeau officer: General Counsel 7005 SOUTHFRONT ROAD, LIVERMORE CA 94551